Navigation Links
Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study

COPENHAGEN, June 21, 2007-Novo Nordisk today announced clinical results from the first of five phase 3 studies with liraglutide - the once-daily human GLP-1 analogue. The 26-week study is part of the LEAD(TM) (Liraglutide Effect and Action in Diabetes) programme and included 581 patients with type 2 diabetes inadequately controlled by two of the most widely used oral antidiabetic drugs: metformin and a sulfonylurea (glimepiride). All patients in the study continued the two oral drugs and were randomised to add one daily injection of liraglutide, placebo or insulin glargine.

The average HbA1c level at the beginning of the study was between 8.0% and 8.5% and at the end of the study, more than 50% of patients in the liraglutide group had reached the American Diabetes Association goal of HbA1c < 7%. Furthermore, more than 35% achieved the American Association of Clinical Endocrinologists HbA1c target of <= 6.5%. The HbA1c reduction achieved in the liraglutide group was more than 0.2 percentage points better than in the insulin glargine group, a difference which is statistically significant.

The average weight of the patients at the beginning of the study was approximately 85 kg. At the end of the study, the difference in body weight between the liraglutide and insulin glargine treatment groups was on average 3.5 kg, statistically significant in favour of liraglutide.

Liraglutide in combination with metformin and glimepiride was well tolerated. The most frequently reported adverse event in the liraglutide arm was nausea at an absolute level of between 10 and 15%. As expected, the combination of a GLP-1 analogue with a sulfonylurea leads to some of the patients experiencing hypoglycaemia. The overall hypoglycaemia event rate in the liraglutide and insulin glargine groups was not significantly different.

Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk, said: "We are very
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
2. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
3. Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients
4. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
5. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
6. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
7. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
8. 2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion
Post Your Comments:
(Date:8/21/2014)... Aug. 21, 2014   Royal Philips ... announced it has received 510(k) clearance from the ... precision planning application for Transcatheter Aortic-Valve Implantation (TAVI) ... provides interventionalists with pre-procedural, high-precision positioning to treat ... planning application is available as part of Philips ...
(Date:8/21/2014)... 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a ... medicine, announced today the appointments of Andrew ("Andy") Arno ... Board of Directors. With these additions, the Asterias Board ... are independent. Andy Arno , 55, ... companies. He is currently Managing Director of Emerging Growth ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down meth offenders and make arrests. Data released ... Indiana blocked the sale of more ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... Calif., Oct. 28 Watson Pharmaceuticals, Inc. (NYSE: ... announced today that its subsidiary Watson Laboratories, Inc. ... on outstanding patent litigation related to Watson,s Oxytrol® ... August 19, 2008, Barr submitted an Abbreviated New ...
... 27 Cambrex Corporation (NYSE: CBM ) announced that third quarter 2009 financial results will be ... conference call to discuss the third quarter 2009 financial results. , , ... 2009 Earnings Conference Call, When: ... 1-888-634-4003 for U.S., ...
Cached Medicine Technology:Watson and Barr Settle Lawsuit Over Oxytrol(R) 2
(Date:8/21/2014)... born at a low or very low birth weight ... 2 diabetes. The findings, which appear in Diabetes ... of type 2 diabetes in African American populations, which ... Researchers from Boston University,s Slone Epidemiology Center followed more ... Study over the course of 16 years, analyzing characteristics ...
(Date:8/21/2014)... -- Being born at a low birth weight puts black ... study suggests. The findings may partly explain high diabetes ... prevalence of low birth weight, the researchers added. Their ... with a low birth weight were 13 percent more likely ... birth weight. The risk of diabetes was 40 percent higher ...
(Date:8/21/2014)... New York (PRWEB) August 21, 2014 ... against C.R. Bard, Inc. continue to move forward ... District Court, Southern District of West Virginia, Bernstein ... issued on August 14th, the Court has established ... that requires special handling, division, storage and preservation. ...
(Date:8/21/2014)... rural communities do not routinely screen women for ... medical and public health researchers. Rural women who ... if they seek help., "Rural health care providers ... S. McCall-Hosenfeld, a primary care physician and assistant ... State College of Medicine. "However, in rural settings, ...
(Date:8/21/2014)... The world wound care market is ... and reach USD 18.3 billion by 2019, posting a ... of such growth include governments’ contribution to the development ... and surging ageing population. However, the growth could be ... Region-wise, North America leads the global wound care market, ...
Breaking Medicine News(10 mins):Health News:Low birth weight linked to higher incidence of type 2 diabetes in African American women 2Health News:Low Birth Weights May Put Black Women at Risk for Diabetes 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 3Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 3
... U-M physician include economical options , , ... of cologne, a new pair of pajamas or a video game are ... holiday season. But this year, why not give something more healthy and ... , , Staying healthy around the ...
... Christopher Horvath, D.V.M., as Vice President of Preclinical Sciences ... , , CAMBRIDGE, Mass., ... Cambridge, Mass.-based executive team with the appointment of Jeffrey ... also announced the additions of Christopher Horvath, D.V.M., as ...
... December, Anthem Blue,Cross is giving the gift of health ... the state offering free health evaluations. Launching,on Monday, ... California,the bus will depart on a multi-city tour to ... Francisco (see detailed schedule,below). , ...
... College 2008 Dreams Come True event. , ... New York, NY (PRWEB) ... sponsor a U.S. chapter of KCA College for Keep A Child Alive, ... the world. KCA College is an action-oriented network of college students ...
... portal, HeadHunterHealthExchange.com allows employers and recruiters to use just one ... candidates online to jobs posted by different employers across the ... hiring more efficent. The Exchange simplifies and expedites the hiring ... ...
... the Dec. 1 issue of the journal Sleep ... and a strict sleep schedule can help night-shift workers create ... performance and alertness during night shifts while still allowing adequate ... performance was better for the experimental subjects than the controls. ...
Cached Medicine News:Health News:Giving the Gift of Health This Holiday Season 2Health News:Giving the Gift of Health This Holiday Season 3Health News:Giving the Gift of Health This Holiday Season 4Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 2Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 3Health News:Anthem Blue Cross Gives the Gift of Health to California 2Health News:Anthem Blue Cross Gives the Gift of Health to California 3Health News:My Bank Tracker Sponsors "Keep A Child Alive" 2Health News:HeadHunterHealthExchange.com Launched to Enhance Healthcare Recruitment for Employers and Recruiters 2Health News:HeadHunterHealthExchange.com Launched to Enhance Healthcare Recruitment for Employers and Recruiters 3Health News:Study shows how shift workers can improve job performance and implement a realistic sleep schedule 2Health News:Study shows how shift workers can improve job performance and implement a realistic sleep schedule 3
... Drapes have aggressive adhesive with no ... adhesion. It's made of thin, low ... with allow-glare matte finish film. Includes ... ,Available sterile in a box of ...
... procedure drape made of 3M™ Steri-Drape™ Absorbent ... create a sterile field during procedures on ... and convenient by eliminating the need for ... extremity drapes with elastic apertures suitable for ...
The Abbott Commander is an automated, high-throughput immunoassay testing system. The Commander System consists of the Flexible Pipetting Center, the Parallel Processing Center, and the Dynamic Incub...
... sample preparation platform is an efficient system ... from patient samples using novel magnetic particle ... sample preparation and is cabable of processing ... a 1 ml sample volume., ,This platform ...
Medicine Products: